April 4 (Reuters) - The Centers for Medicare & Medicaid Services said on Friday that it did not move forward with a proposal put forth by the Biden administration on Medicare coverage of weight-loss drugs such as Novo Nordisk's NOVOb.CO Wegovy.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.